Results 71 to 80 of about 2,507,641 (307)

Contemporary update on neoadjuvant therapy for bladder cancer.

, 2017
Administration of neoadjuvant chemotherapy preceding radical cystectomy in patients with bladder cancer remains a matter of debate. Results of prospective, randomized studies have demonstrated an overall absolute survival benefit of 5% at 5 years ...
George N. Thalmann, Nguyen, Daniel Truong Phat, Thalmann, George, Daniel P. Nguyen   +3 more
core   +1 more source

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

Advanced Materials, EarlyView.
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi, Sang Nam Lee, Jang Hun Heo, Soyoung Park, Sei Hyun Park, Yong Taik Lim   +5 more
wiley   +1 more source

Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

Cancer Immunology, Immunotherapy
Objective Hypopharyngeal squamous cell carcinoma (HSCC) is a highly malignant tumor type in the head and neck region. In recent years, neoadjuvant therapy has significantly improved the laryngeal preservation rate among patients.
Gaofei Yin, Nuan Li, Xiaohong Chen, Yang Zhang, Zhigang Huang, Wei Guo   +5 more
doaj   +1 more source

Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2022
The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China.
CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong   +3 more
doaj   +1 more source

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

, 2021
Neoadjuvant therapies, primarily chemotherapy and chemoradiotherapy, are able to improve the overall survival (OS) in patients with locally advanced resectable esophageal cancer (EC) based on the results of several randomized clinical trials.
Sicong Hou, Yanbing Ding, Qinglei Hang, Ziyin Pan, Xin Hao   +4 more
core   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Translational Oncology
Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking.
Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu   +5 more
doaj   +1 more source

Neoadjuvant Therapy in Pancreatic Cancer: Review Article [PDF]

, 2015
Context Pancreatic cancer is still associated with a high mortality and morbidity for affected patients. To this date the role of neoadjuvant therapy in the standard treatment of pancreatic cancer remains elusive.
Deichmann, Steffen, Pross, Moritz, Jung, Carlo, Honselmann, Kim C, Keck, Tobias, Bausch, Dirk, Wellner, Ulrich F   +6 more
core   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Neoadjuvant therapy for pancreatic cancer

British Journal of Surgery, 2007
No good evidence of benefit—trials ...
J, Kleeff, H, Friess, M W, Büchler
openaire   +2 more sources